Try our beta test site
1 study found for:    NCT01142401
Show Display Options
Rank Status Study
1 Active, not recruiting Fulvestrant With or Without Bortezomib in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Conditions: Estrogen Receptor Positive;   Recurrent Breast Carcinoma;   Stage III Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Bortezomib;   Drug: Fulvestrant;   Other: Laboratory Biomarker Analysis

Study has passed its completion date and status has not been verified in more than two years.